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To assess safety, tolerability, and eﬃcacy of the antigen-speciﬁc immunotherapy ATX-MS-1467
in participants with relapsing multiple sclerosis using diﬀerent treatment protocols to induce
tolerance.
Methods
Two open-label trials in adult participants with relapsing multiple sclerosis were conducted.
Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1)
with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX-
MS-1467 dosed at 25, 50, 100, 400, and 800 μg at 14-day intervals over 8 weeks, followed by 8
weeks with 4 additional 800-μg doses at 14-day intervals and 32 weeks oﬀ study medication.
Study 2 was a phase 2a, multicenter, single-arm trial enrolling 37 participants. ATX-MS-1467
was titrated from 50 μg i.d. on day 1 to 200 μg on day 15 and 800 μg on day 29 followed by
biweekly administration of 800 μg for 16 weeks and 16 weeks oﬀ study medication. Eﬃcacy was
evaluated on MRI parameters and clinical variables. Safety endpoints included treatment-
emergent adverse events and injection-site reactions.
Results
In study 1, there was a signiﬁcant decrease in new/persisting T1 gadolinium-enhanced (GdE)
lesions in cohort 1 from baseline to week 16, returning to baseline values at week 48. In study 2,
the number of T1 GdE lesions were signiﬁcantly reduced on treatment and remained reduced
at study completion. Safety results were unremarkable in both studies.
Conclusion
Relatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated
with reduction in GdE lesions and a sustained eﬀect post treatment. Further trials of ATX-MS-
1467 are warranted.
Classification of evidence
This work provides Class IV evidence that for patients with relapsing multiple sclerosis, slow
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By aiming to reinstate tolerance to the protein causing the
disease,1 antigen-speciﬁc immunotherapy represents a major
conceptual shift away from most current and emerging im-
munomodulatory therapies for multiple sclerosis (MS).2–7
Peripheral tolerance is mediated by steady-state dendritic cells
when peptides bind to major histocompatibility complex class
II molecules at their surface, promoting interaction with
antigen-speciﬁc T cells and subsequent generation of regula-
tory CD4+ T cells.8 The risk of an immune response can be
avoided during tolerance induction by the use of synthetic
peptides that mimic naturally processed CD4+ T cell
epitopes.9,10 Such peptides have been termed apitopes, short
for antigen-processing independent epitopes.11
We have identiﬁed epitopes from 4 regions of myelin basic
protein (MBP) that behave as apitopes but also induce tol-
erance to myelin and reduce disease severity by up to 95% in
a humanized mouse model when administered sub-
cutaneously (s.c.) as a cocktail (ATX-MS-1467).11 In an initial
phase 1 trial of 6 participants with secondary progressive MS,
ATX-MS-1467 was well tolerated, and there were signiﬁcant
immunologic changes consistent with a clinical eﬀect on T cell
responses to MBP 1 month after treatment compared to
visit 1.11
The most appropriate ATX-MS-1467 titration scheme still
needs to be identiﬁed. Accordingly, we performed 2 follow-up
studies in participants with relapsing MS (RMS): one phase
1b ascending-dose safety evaluation comparing intradermal
(i.d.) with s.c. administration and one proof-of-concept phase
2a trial assessing the eﬀects on MRI parameters of ATX-MS-
1467 administered i.d. and using a shorter dose-escalation
phase with a prolonged highest-dose period.
Methods
Primary research questions
The aim of the 2 studies was to assess safety, tolerability, and
eﬃcacy of ATX-MS-1467 in RMS using diﬀerent treatment
protocols to induce tolerance.
Standard protocol approvals, registrations,
and patient consents
Both studies were entered into public registries: the phase
1b study in the European Clinical Trials Database (number
2009-016710-25) and the phase 2a study on the Clin-
icalTrials.gov registry (identiﬁer: NCT01973491). The
studies were conducted in accordance with all applicable
regulations, including the International Conference on Har-
monisation Good Clinical Practice Guidelines and the ethical
principles in the Declaration of Helsinki,12 as well as local
regulations and standards. The appropriate institutional re-
view boards or regional review boards approved the use of
human subjects for the studies. All participants gave written
informed consent.
Participants
The studies were open-label trials in adult participants aged 18
to 55 years (study 1) and 18 to 65 years (study 2), re-
spectively, with RMS (≥1 documented relapse in the previous
12 months or 2 relapses within the previous 24 months), as
deﬁned by the McDonald 2010 criteria,13 positive for
human lymphocyte antigen (HLA)-DRB1*15, and with Ex-
panded Disability Status Scale (EDSS) scores ≤5.5. Prior and
concomitant disease-modifying therapies were prohibited,
except for interferon beta where adequate washout was re-
quired prior to study entry. Corticosteroids were permitted to
treat relapses.
Phase 1b study (study 1)
The phase 1b study was a multicenter, 2-arm, ascending-dose
safety and proof-of-principle study with the primary objective
to assess the safety of ATX-MS-1467. Secondary objectives
were to assess, on an exploratory level, the eﬀect of ATX-MS-
1467 on brain MRI (gadolinium-enhanced [GdE], 1.5-tesla
MRI scanning).
The study enrolled 43 participants at 9 centers in the Russian
Federation and 2 centers in the United Kingdom. Participants
were divided into 2 cohorts. ATX-MS-1467 was administered
i.d. in cohort 1 and s.c. in cohort 2. Participants were allocated
to a cohort consecutively in the order of enrollment into the
study. Dosing, titration, and intervals (ﬁgure 1A) were based
on the earlier phase 1 study.11 Over an 8-week titration period,
both cohorts received increasing doses of ATX-MS-1467 of
25, 50, 100, 400, and 800 μg at 14 ± 3 day intervals. The
titration period was followed by an 8-week, full-dose period
during which participants received 4 additional 800-μg doses
at 14 ± 3 day intervals. Participants were then followed for an
additional 32 weeks oﬀ study medication.
Safety was assessed by the incidence of adverse events (AEs)
and treatment-emergent AEs (TEAEs), examination of safety
laboratory values, anti-peptide antibody tests, urine preg-
nancy tests, vital signs, physical examination, neurologic ex-
amination, and MRI evaluation of brain lesions. A TEAE was
Glossary
AE = adverse event; ARR = annualized relapse rate; EDSS = Expanded Disability Status Scale; GdE = gadolinium-enhanced;
i.d. = intradermal; ITT = intention-to-treat;MBP = myelin basic protein; mITT = modiﬁed intention-to-treat;MS = multiple
sclerosis;MSFC = Multiple Sclerosis Functional Composite; RMS = relapsing multiple sclerosis; s.c. = subcutaneous; TEAE =
treatment-emergent adverse event.
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deﬁned as an AE occurring on or after the ﬁrst administration
of ATX-MS-1467 and no later than week 20. A data moni-
toring committee reviewed the combined safety data for co-
hort 1 after the last dose of 800 μg was administered to the ﬁrst
10 and 20 participants, respectively. The primary safety
endpoints were evaluated on an ongoing basis up to week 20
and again at week 48. Safety was analyzed in the intention-to-
treat (ITT) population, deﬁned as all participants who re-
ceived ≥1 administration of ATX-MS-1467 any time during
the study.
Eﬃcacy was assessed based onMRI evaluation of brain lesions
as part of the safety evaluation on a proof-of-principle basis.
Analyses included the presence of new T1 GdE lesions, new
or enlarged T2 hyperintense lesions, and T1 hypointense
lesions. The analyses were performed on the MRI population,
deﬁned as the per-protocol population (all ITT participants
who complied with the protocol up to and including the week-
20 visit).
In this explorative study, no formal sample size calculation was
performed, and p values are presented for descriptive pur-
poses only.
In both studies, continuous variables are summarized de-
scriptively using the number of observations, means ± SD,
95% conﬁdence interval, median, minimum, and maximum.
Categorical variables are summarized using frequency counts
and percentages.
Phase 2a study (study 2)
The phase 2a study was a multicenter, single-arm, proof-of-
concept trial at 7 sites in the Russian Federation and 1 site in
Latvia. The primary objective was to evaluate the eﬀects of
Figure 1 Designs of the 2 studies
Time course, titration schemes, andassessment points are shown for the 2 studies. (A) Study 1 (phase 1b study); (B) study 2 (phase 2a study). Triangles indicate
MRI measurements. i.d. = intradermal; s.c. = subcutaneous.
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ATX-MS-1467 administered i.d. compared with a baseline
control period oﬀ treatment. Safety evaluation was a second-
ary objective.
The dosing, escalation, and intervals diﬀered from the phase 1
studies in that a shorter titration regimen was used, followed by
a longer highest-dose treatment period (ﬁgure 1B). During
a 4-week titration period, the dose of ATX-MS-1467 was ti-
trated from 50 μg on day 1 to 200 μg on day 15 and 800 μg on
day 29. Subsequently, participants received biweekly adminis-
tration of 800 μg ATX-MS-1467 for 16 weeks. Participants were
then followed for an additional 16 weeks oﬀ study medication.
Eﬃcacy was evaluated on MRI parameters and clinical vari-
ables. The primary endpoint was change in the number of T1
GdE lesions at the last 3 on-treatment scans compared with
the number of T1 GdE lesions at the 3 baseline scans. Sec-
ondary endpoints included number and change from baseline
in T1 GdE lesions at each visit post baseline, the number of
new or newly enlarging T2 lesions post baseline, mean an-
nualized relapse rate (ARR) at week 20, time to ﬁrst relapse,
and change from baseline in total EDSS scores and in total
Multiple Sclerosis Functional Composite (MSFC) scores,
both assessed at week 20. Relapses were objectively assessed
by the investigator.
Safety endpoints included TEAEs, injection-site reactions,
vital signs, clinical laboratory variables, ECGs, and the fre-
quency and timing of premature study termination. A TEAE
was deﬁned as any AE occurring on or after the ﬁrst dose and
within 28 days after the date of last dose.
The sample size calculation assumed a 70% reduction in GdE
lesions with treatment compared with baseline, with 5 ± 6
GdE lesions on average at baseline and 1.5 ± 1.8 GdE lesions
on average during the posttreatment period.14 Using a 2-sided
5% level, >80% and >90% power was reached with sample
sizes of 12 and 14 participants, respectively. Thus, a sample
size of 15 participants was selected.
Primary and secondary endpoints were analyzed in the
modiﬁed ITT (mITT) population, which included all en-
rolled participants who received ≥1 dose of ATX-MS-1467
and had ≥2 MRI scans during the baseline control period and
≥2 MRI scans during planned on-treatment visits. Mainte-
nance of response was analyzed in the “responders” pop-
ulation (participants in whom there was a ≥60% reduction
from baseline in the number of T1 GdE lesions at week 20),
and safety analyses were based on the safety population.
The primary endpoint was analyzed using a nonparametric
Wilcoxon signed rank test. A supportive analysis was performed
to estimate mean percentage reduction from baseline in new
T1 GdE lesions using a generalized estimating equations linear
regression model with negative binomial and Poisson link
functions. Descriptive statistics were used for secondary end-
points at each applicable visit for themITT analysis set. Time to
event variables are presented as Kaplan-Meier estimates, me-
dian survival, and 95% conﬁdence interval.
Results
Study populations
Flow diagrams for the 2 studies are shown in ﬁgure 2. In study
1, the ITT population consisted of 43 participants, the per-
protocol population of 35, and the MRI population of 37
participants. A total of 42 participants completed the treat-
ment phase of the study: 20 in cohort 1 and 22 in cohort 2.
Nineteen participants in cohort 1 and 20 participants in co-
hort 2 completed the follow-up period; 2 participants dis-
continued and 1 was lost to follow-up. One participant
attended all follow-up visits but did not receive the last dose of
ATX-MS-1467 because of concerns of an allergic reaction and
was not included in the follow-up analysis population.
In study 2, 37 participants were enrolled, of whom 19 com-
pleted the titration period and were included in the ITT,
mITT, and safety populations. One participant discontinued
before the end of the treatment period (because of diarrhea,
recorded as an AE) and one participant withdrew consent
after completing the treatment period. Seven participants
demonstrated a ≥60% reduction from baseline in the number
of T1 GdE lesions at week 20 and were included in the re-
sponder population.
Demographic characteristics at baseline are shown in the
table. In both studies, all participants were Caucasian with
mean ages approximately 30 years and 70% female. EDSS
scores and number of MS relapses in the last 24 months were
similar in both studies. The study 1 population had fewer GdE
lesions at baseline (2.8 ± 6.80) than the study 2 population
(7.4 ± 7.62).
Efficacy results
In study 1, there was a signiﬁcant 73% decrease in the number
of new or persisting GdE lesions in cohort 1 from 3.4 ± 8.23 at
baseline (week 0) to 0.9 ± 1.67 at week 16 (p = 0.030;
ﬁgure 3A). The number of new or persisting lesions had
returned to baseline values by study end. In cohort 2, the
mean number of new or persisting GdE lesions was relatively
low throughout the study, increasing moderately to week 16
but returning to close to baseline values by week 48. The
values were considered to represent normal variation.
The total volume of GdE lesions in cohort 1 decreased from
0.305 mL at study day 1 to 0.137 mL at week 16 (a 0.187 mL
decrease) and remained reduced at week 48. The lowest value
(0.094 mL) was measured at week 36 (ﬁgure 3B). In cohort 2,
there was greater variability throughout, and the lesion vol-
ume at week 48 was comparable to that at baseline.
At week 48, 70.6% (12/17) of participants in cohort 1
were free of GdE lesions, an increase from 52.9% (9/17) at
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baseline. In cohort 2, the percentages of participants free of
GdE lesions were comparable at baseline and week 48. There
were no notable changes in the mean number of new or newly
enlarging T2 hyperintense lesions.
In study 2, there was a statistically signiﬁcant decrease in the
number of T1 GdE lesions on treatment (average of up to 3
measurements at weeks 12, 16, and 20) compared with
baseline (from 7.4 ± 7.62 to 5.0 ± 7.24; p = 0.0143) based on
a nonparametric analysis. Number and volume of T1 GdE
lesions remained reduced from the end of the treatment
period to the study end (ﬁgure 4). The mean reduction in
lesions from baseline ranged from 1.6 to 4.6, and the re-
duction in lesion volume ranged from 0.579 to 0.225 mL.
Changes from baseline to the end of treatment in EDSS and
MSFC scores were not signiﬁcant. There were numerical
improvements (p = 0.054, Wilcoxon matched-pairs signed
rank test) during the study in the MSFC score from baseline
to the end of the treatment period. This observation drove
a post hoc analysis on the MSFC individual score compo-
nents. The Paced Auditory Serial Addition Test score
Figure 2 Flow diagrams
Schematic flow diagrams with partici-
pant disposition for (A) study 1 (phase
1b study) and (B) study 2 (phase 2a
study), respectively. aCompleted all 9
doses of ATX-MS-1467 and week-20
visit, battended week-48 visit, centered
the baseline control period, dvisits 8 to
15 (weeks 6–20). AE = adverse event;
i.d. = intradermal; s.c. = subcutaneous.
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improved signiﬁcantly (p = 0.01) from week 0 to the end of
the treatment period.
During study treatment, 3 participants (15.8%) experienced
single relapses (on days 50, 59, and 89, respectively) corre-
sponding to an ARR of 2.60 for these patients (0.41 for the
study population). Participants received rescue corticosteroid
therapy. A≥85% treatment eﬀect wasmaintained betweenweek
20 and study end for 57% of those participants (7) of the study
population who showed >60% decrease in new T1 lesions.
Safety and tolerability
In study 1, 33 participants (77%) experienced a TEAE, all of
which were mild or moderate. Twenty participants (47%)
experienced treatment-related TEAEs, 14 in cohort 1 (67%)
and 6 (27%) in cohort 2. The greater number of participants
reporting a treatment-related AE in cohort 1 (i.d. adminis-
tration) was attributable to a higher number of injection-site
reactions (for details, see table e-1, links.lww.com/WNL/
A245). In both cohorts, all treatment-emergent injection-site
reactions were mild. There were no treatment-related early
discontinuations. One patient in cohort 1 discontinued the
treatment phase because of an AE (allergic reaction) possibly
related to the study medication. There were no severe TEAEs,
no treatment-related serious AEs, and no AEs that resulted in
dose suspension or withdrawal from the study. There were no
reports of drug-related MS relapse in either cohort, nor were
there any antibody responses to any ATX-MS-1467 peptides.
Treatment-emergent MS relapses were experienced by 2
participants in cohort 1 at weeks 14 and 16, respectively. In
cohort 2, 1 participant experienced 2 relapses after treatment
at 400 μg and at 800 μg (weeks 6 and 8) and 2 subjects after
treatment at 800 μg (weeks 8 and 16). This corresponded to
a mean total cohort ARR of 0.15. All participants received
steroid rescue therapy and recovered. All relapses were mild
or moderate and none was assessed as related to treatment.
In study 2, 15 participants (79%) experienced a TEAE. All
were mild or moderate. Eleven TEAEs (58%) were identiﬁed
as treatment-related. The majority were injection-site reac-
tions: erythema in 5 participants (26%), induration, pain, and
Table Demographic characteristics of the study
populations at baseline
Variable
Study 1 (n = 43)a
Study 2 (n = 19)bCohort 1 Cohort 2
Age, y 33.0 ± 9.5 31.6 ± 9.6 27.1 ± 5.5
Sex, female 17 (81) 13 (59) 15 (79)
Height, cm 164.9 ± 7.9 168.9 ± 8.1 168.8 ± 6.9
Weight, kg 66.2 ± 15.6 67.8 ± 12.8 65.49 ± 16.7
BMI, kg/m2 24.24 ± 4.9 23.70 ± 3.6 22.78 ± 4.4
EDSS score 2.52 ± 0.9 2.05 ± 0.8 2.32 ± 0.8
MSFC score NA NA 0.289 ± 0.52
No. of T1 GdE lesionsc 3.4 ± 8.2 2.3 ± 5.5 7.4 ± 7.6
Volume of T1
GdE lesions, mLc
0.305 ± 0.61 0.189 ± 0.43 0.838 ± 1.02
MS relapses in
previous 24 mo
1–2 18 (86) 22 (100) 17 (90)




NA NA 4.2 ± 3.3
Abbreviations: ARR = annualized relapse rate; BMI = body mass index;
EDSS = Expanded Disability Status Scale; GdE = gadolinium-enhanced; MS =
multiple sclerosis; MSFC =Multiple Sclerosis Functional Composite; NA = not
assessed.
Data represent either mean ± SD or n (%).
a Intention-to-treat population.
b Safety population.
c MRI population; n = 37.
d ARRwas estimated from the numbers of recorded relapses in the previous
24months. The lowest value in the range assumes that all patients had 1 or 3
relapses, respectively; the high range assumes 2 or 4 relapses.
Figure 3 Efficacy results in study 1
Number (A) and volume (B) of new or persisting gadolinium (Gd)-enhancing
T1 lesions over time in the study 1 cohort 1 per-protocol population (n = 16).
Values are mean ± SEM (A) and mean ± SD (B) respectively.
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pruritus each in 2 participants (11%), and hemorrhage in 1
participant (5%). Two participants (11%) experienced
treatment-related diﬀuse alopecia. One participant dis-
continued treatment because of a TEAE of prolonged, mod-
erate diarrhea, which was considered treatment-related.
Discussion
ATX-MS-1467 is being developed as a potential immuno-
therapy for MS targeting speciﬁcally the autoreactive immune
system directed against myelin. This strategy diﬀers from
most emerging therapies for MS, which use monoclonal
antibodies to target and modify diﬀerent aspects of the im-
mune system.15,16 Although an appealing concept, no peptide-
based antigen-speciﬁc immunotherapy has yet been successful
in MS. The results presented here, from a phase 1b and
a phase 2a study, further support ATX-MS-1467 as a poten-
tially eﬀective and well-tolerated new therapy.
Dosing and titration regimens are important for antigen-
speciﬁc immunotherapy. To induce eﬀective tolerance with
ATX-MS-1467, a reasonably high dose is considered neces-
sary, as 3 of the 4 MBP peptides in this cocktail display low
aﬃnity for major histocompatibility complex binding sites.11
Earlier work has demonstrated the critical role of a dose-
escalation protocol in minimizing CD4+ T cell activation and
proliferation during the early stages of immunotherapy, to
prevent excessive systemic cytokine release and allow safe
administration of the required doses.8 The 2 trials described in
the present communication provide further information to
guide an optimized escalation and treatment scheme for ATX-
MS-1467 in RMS.
In study 1, a slower 8-week titration period was followed by an
8-week, full-dose treatment period. This corresponded to the
regimen in the ﬁrst in-human study with ATX-MS-1467.11
Study 2 used a shorter 4-week titration period and a longer 16-
week, full-dose treatment period. In both trials, treatment was
associated with reductions in the number of T1 GdE lesions,
a biomarker for inﬂammatory disease activity.17,18 In study 2,
the median number of new/enlarging T2 lesions decreased
after week 12 and remained reduced at subsequent visits. Of
note, there were no safety and tolerability concerns associated
with any treatment regimen.
In study 1, the reduction in the number of T1 GdE lesions was
greater than the reductions in study 2. However, in the latter
trial, the longer full-dose treatment period led to a greater
persistence of the eﬀect during oﬀ-treatment follow-up.
Taken together, these eﬀects on new GdE lesions are com-
parable to those reported for other MS therapies at similar
stages of development.15
Although results cannot be directly compared between 2
separate trials, they clearly show that the rate of dose escala-
tion can have a signiﬁcant eﬀect on eﬃcacy (whereby a longer
dose escalation appears to be more favorable). This ﬁnding is
supported by preclinical data.8 In addition, longer treatment
with the highest dose appears to oﬀer a longer-lasting eﬀect
post treatment.
The diﬀerence in outcomes between the 2 cohorts in study 1
is consistent with the i.d. route of administration being opti-
mal for immunotherapy with peptides. It does not exclude the
eﬃcacy of the s.c. route, as cohort 2 had fewer GdE lesions at
baseline and limited scope for improvement. The consistently
low disease activity throughout the course of treatment in
cohort 2may be attributable to a protective eﬀect of ATX-MS-
1467, but such conclusions are speculative.
Both studies have limitations, particularly the lack of placebo
group or randomization, as well as small cohort sizes. In study
1, eﬃcacy was evaluated on secondary endpoints. The Paced
Auditory Serial Addition Test results should not be over-
interpreted, because the score is susceptible to practice eﬀects,
particularly during a short trial.19 Despite the limitations,
these 2 trials, using validated MRI surrogate endpoints20 and
established outcomes for proof-of-concept and phase 2 eﬃ-
cacy trials in RMS,21 support the use of a relatively slow ATX-
Figure 4 Efficacy results in study 2
Number (A) and volume (B) of new or
persisting gadolinium (Gd)-enhanc-
ing T1 lesions over time in the study 2
per-protocol population (n = 16).
Bars and lines represent mean ±
SEM. On treatment represents the
average of up to 3 measurements
taken at weeks 12, 16, and 20. Post
treatment represents the average of
up to 2 measurements taken at
weeks 28 and 36. *p < 0.05; **p <
0.01; ***p < 0.001.
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MS-1467 titration procedure combined with a longer full-
dose treatment period to achieve eﬀective reduction in T1
GdE lesions during treatment and a sustained eﬀect post
treatment. A further phase 2b trial of ATX-MS-1467 in
a larger study population is warranted to conﬁrm these
ﬁndings.
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Studies 1 and 2 were registered with the European Clinical Trials
Database (number 2009-016710-25) and ClinicalTrials.gov
(identiﬁer: NCT01973491), respectively.
Study question
Under which treatment protocols can ATX-MS-1467 safely and
eﬀectively treat relapsing MS (RMS)?
Summary answer
With slow titration and long full-dose treatment periods, in-
tradermal ATX-MS-1467 can safely reduce the number of lesions
in patients with RMS.
What is known and what this paper adds
A previous small Phase 1 trial provided preliminary evidence that
ATX-MS-1467 is tolerable and eﬀective for multiple sclerosis, but
the most appropriate titration schemes need to be identiﬁed. This
study provides Class IV evidence for the safety and eﬃcacy of ATX-
MS-1467 for RMS under diﬀerent titration schemes.
Participants and setting
Study 1 (ncompleted = 39) involved 9 Russian centers and 2 British
centers, and study 2 (ncompleted = 18) involved 7 Russian centers
and a Latvian center. All participants were adults with RMS, de-
ﬁned as at least one relapse in the previous 12 months or 2 in the
previous 24, and Expanded Disability Status Scale scores of ≤5.5.
Design, size, and duration
The study 1 participants received subcutaneous (ncompleted = 20)
or intradermal (ncompleted = 19) ATX-MS-1467 administration
over an 8-week escalating dose period and an 8-week full-dose
period; they were examined oﬀ-medication for 32 weeks. The
study 2 participants received intradermal ATX-MS-1467 admin-
istration over a 4-week escalating dose period and a 16-week full-
dose period; they were examined oﬀ-medication for 16 weeks.
Primary outcomes
The primary outcome was the change in the number of visible
lesions between pre-study T1 MRI scans and on-treatment T1
MRI scans.
Main results and the role of chance
The study 1 participants who received intradermal ATX-MS-
1467 exhibited a reduction from baseline in new and persistent
lesions at week 16 (p = 0.030), although the number had
increased by week 48. The study 2 participants exhibited a re-
duction from baseline in lesion numbers throughout the study
period (p = 0.0143).
Harms
No major adverse events were noted.
Bias, confounding, and other reasons
for caution
The studies had small samples sizes, no placebo groups, and no
randomization.
Generalizability to other populations
Further studies with larger sample sizes are necessary to establish
the generalizability of the results.
Study funding/potential competing interests
The studies were funded by Merck KGaA Darmstadt
Germany. Some authors report receiving funding and per-
sonal compensation from pharmaceutical companies, holding
patents, receiving funding from government agencies, and
various other disclosures. Go to Neurology.org/N for full
disclosures.
Figure Number of new or persisting gadolinium-enhanced
T1 MRI lesions over time in Study 2 participants
Bars and lines represent means ± SEMs. “Pre” represents pre-study meas-
urements. “On” represents the average of up to 3 measurements taken in
weeks 12, 16, and 20. “Post” represents the average of up to 2 measure-
ments taken in weeks 28 and 36. *p < 0.05.
A draft of the short-form article was written by M. Daleﬁeld, a writer with Editage, a division of Cactus Communications. The authors of the
full-length article and the journal editors edited and approved the ﬁnal version.
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